romidepsin sold brand name istodax anticancer agent used cutaneous tcell lymphoma ctcl peripheral tcell lymphomas ptcls romidepsin natural product obtained bacterium chromobacterium violaceum works blocking enzymes known histone deacetylases thus inducing sometimes referred depsipeptide class molecules belongs romidepsin branded owned gloucester pharmaceuticals part romidepsin first reported scientific literature team researchers fujisawa pharmaceutical company astellas pharma tsukuba japan isolated culture chromobacterium violaceum soil sample obtained yamagata found little antibacterial activity potently cytotoxic several human cancer cell lines effect normal cells studies mice later found antitumor activity vivo first total synthesis romidepsin accomplished harvard researchers published mechanism action elucidated researchers fujisawa university tokyo found histone deacetylase inhibitor effects similar trichostatin phase studies romidepsin initially codenamed began phase ii phase iii trials conducted variety indications significant results found treatment cutaneous tcell lymphoma ctcl peripheral tcell lymphomas romidepsin received fast track designation fda treatment cutaneous tcell lymphoma orphan drug status fda european medicines agency fda approved romidepsin ctcl november approved romidepsin peripheral tcell lymphomas ptcls june randomised phase iii trial romidepsin chop chemotherapy vs chop chemotherapy patients peripheral cell lymphoma returned negative results significant impact progression free survival overall plos pathogens published study involving romidepsin trial designed reactivate latent hiv virus order deplete hiv reservoir latently infected tcells exposed vitro ex vivo romidepsin leading increase detectable levels cellassociated hiv rna trial also compared effect romidepsin another histone deacetylase inhibitor study involving romidepsin animal study showed brief treatment low amounts romidepsin could reverse social deficits mouse model phase ii trial romidepsin involving patients ctcl ptcl evidence increased histone acetylation peripheral blood mononuclear cells pbmcs extending hours expression gene marker romidepsininduced gene expression also increased pbmcs tumor biopsy samples increased gene expression following increased histone acetylation expected effect hdac inhibitor increased hemoglobin f another surrogate marker geneexpression changes resulting hdac inhibition also detected blood romidepsin administration persistent histone acetylation inversely associated drug clearance directly associated patient response approved dosage romidepsin ctcl ptcl fourhour iv administration days treatment cycle repeated long patient continues benefit tolerate therapy dose reduction possible patients experience highgrade toxicities trials involving patients advanced cancers romidepsin exhibited linear pharmacokinetics across doses ranging administered intravenously four age race sex mildtosevere renal impairment mildtomoderate hepatic impairment effect romidepsin pharmacokinetics accumulation plasma concentration observed repeated romidepsin acts prodrug disulfide bond undergoing reduction within cell release zincbinding thiol binds zinc atom binding pocket zndependent histone deacetylase block activity thus hdac inhibitor many hdac inhibitors potential treatments cancer ability epigenetically restore normal expression tumor suppressor genes may result cell cycle arrest differentiation use romidepsin uniformly associated adverse clinical trials common nausea vomiting fatigue infection loss appetite blood disorders including anemia thrombocytopenia leukopenia also associated infections metabolic disturbances abnormal electrolyte levels skin reactions altered taste perception changes cardiac electrical httpsenwikipediaorgwikiromidepsin